An update on options of therapy for aggressive mantle cell lymphoma.
Mantle celllymphoma
options
therapy
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
28
4
2020
medline:
28
4
2021
entrez:
28
4
2020
Statut:
ppublish
Résumé
With the emerging application of novel targeted agents in the induction, maintenance and salvage strategies, management of aggressive mantle cell lymphoma is being transformed from high-intensity chemo-immunotherapy applicable to only selected patients, to more personalized treatment incorporating novel agents that are effective and accessible for the majority of the patients. This review summarizes risk-stratified management paradigm for aggressive mantle cell lymphoma, providing context for clinical applications of novel agents and cellular therapy including stem cell transplant and CAR-T.
Identifiants
pubmed: 32336184
doi: 10.1080/10428194.2020.1755860
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM